Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ICLR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Jatenzo Oral Product | Hypogonadism | Phase 4 · NCT06385509 | Completed |
| BT524 (Part I) | Congenital Afibrinogenemia | Phase 3 · NCT02065882 | Completed |
| Clascoterone 5% solution | Alopecia, Androgenetic | Phase 3 · NCT05910450 | Completed |
| Clazakizumab | Antibody-mediated Rejection | Phase 3 · NCT03744910 | Terminated |
| Estetrol oral tablet | Vasomotor Symptoms | Phase 3 · NCT04090957 | Completed |
| Padeliporfin | Transitional Cell Cancer of Renal Pelvis and Ureter | Phase 3 · NCT04620239 | Active not recruiting |
| 15 µg H5N1 antigen plus full dose AS03A | Influenza | Phase 2 · NCT06560151 | Completed |
| BXQ-350 Nanovesicle Formulation | Metastatic Colorectal Carcinoma | Phase 1/2 · NCT05322590 | Active not recruiting |
| Tasipimidine | Insomnia | Phase 2 · NCT06956495 | Completed |
| Chlorpheniramine Polistirex | Hepatitis B, Chronic | Phase 2 · NCT02065336 | Terminated |
| Petadeferitrin (SP-420) | Beta Thalassemia Major Anemia | Phase 2 · NCT05693909 | Recruiting |
| Topical Gel HT-001 | Acneiform Eruption Due to Chemical | Phase 2 · NCT05639933 | Recruiting |
| JTT-861 Capsules | Chronic Heart Failure | Phase 2 · NCT06017609 | Completed |
| MVA-BN Smallpox Vaccine | Monkeypox (Mpox) | Phase 2 · NCT07199569 | Active not recruiting |
| MVA-BN (Quail) | Monkeypox (Mpox) | Phase 2 · NCT07199569 | Active not recruiting |
| Napazimone | Mitochondrial Diseases | Phase 2 · NCT07514338 | Recruiting |
Also used in these trials (approved or third-party drugs, not ICLR's own candidates): Belimumab, Anifrolumab, Camizestrant, Cisplatin, Gemcitabine Hydrochloride, Necitumumab, Pegunigalsidase Alfa, Ribociclib, Entecavir, Vosoritide, Tafenoquine, Vamorolone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ICLR holds $809M in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ICLR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Artisan Partners Asset Management Inc. | Institution (13G, 5%+) | 8,361,303 | 10.92% | 2026-02-27 |
| FMR LLC | Institution (13G, 5%+) | 6,594,248 | 8.61% | 2026-09-30 |
| Invesco Ltd. | Institution (13G, 5%+) | 5,264,236 | 6.88% | 2026-06-30 |
| HARRIS ASSOCIATES L P | Institution (13G, 5%+) | 4,351,317 | 5.68% | 2026-03-31 |
| Stephen A Cutler Director |
Insider | 79,278 | 0.10% | 2026-03-18 |
| Barry Edward Balfe Chief Executive Officer, Director · +51,959 options |
Insider | 9,291 | 0.01% | 2026-10-31 |
| Nigel Bernard John Clerkin Chief Financial Officer · +7,573 options |
Insider | 7,171 | 0.01% | 2026-10-31 |
| Ciaran Murray Director · +2,047 options |
Insider | 7,000 | 0.01% | 2026-11-12 |
| Linda Grais Director · +1,324 options |
Insider | 6,162 | 0.01% | 2026-08-10 |
| Ronan Martin Murphy Director · +1,324 options |
Insider | 3,847 | 0.01% | 2026-09-17 |
| Eugene Pacelli McCague Director · +1,324 options |
Insider | 3,811 | 0.00% | 2026-09-17 |
| Julie O'Neill Director · +1,324 options |
Insider | 3,515 | 0.00% | 2026-08-10 |
Share count 76,567,325 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ICLR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →